Phases précoces tumeurs solides
CC-95775-ST-001
A PHASE 1B DOSE ESCALATION, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC AND PHARMACODYNAMIC OF CC-95775 IN SUBJECTS WITH ADVANCED SOLID TUMORS AND RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Paris
CHRISTOPHE LE TOURNEAU
Appareil pulmonaire
AMG 20190009_25004
A Phase 3 Multicenter, Randomized, Open;Label, Active-controlled, Study of AMG 510;Versus Docetaxel for the Treatment of Previously;Treated Locally Advanced and Unresectable or;Metastatic NSCLC Subjects With Mutated;KRAS p.G12C
Paris
NICOLAS GIRARD
Phases précoces tumeurs solides
BET115521
A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma(NMC) and other cancers.
Paris
CHRISTOPHE LE TOURNEAU
VADS
CA223-001
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in;Advanced Refractory Solid Tumors
Paris
CHRISTOPHE LE TOURNEAU
VADS
CHECKMATE 651 (CA209-651)
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Paris
CHRISTOPHE LE TOURNEAU
VADS
COPAN-ORL 06
Phase Ib/II trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) harboring a PI3KCA mutation/amplification and/or a PTEN loss. COPAN - ORL06
Paris
CHRISTOPHE LE TOURNEAU
VADS
DEBIO 1143-201
A Phase I/II randomised study to determine the maximum tolerated dose, safety, pharmacokinetics and antitumor activity of Debio 1143 combined with concurrent chemo-radiation therapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Paris
CHRISTOPHE LE TOURNEAU
VADS
DEBIO 1143-202
Pre-operative window-of-opportunity study of Debio 1143 with or without cisplatin in patients with resectable squamous cell carcinoma of the head and neck.
Paris
CHRISTOPHE LE TOURNEAU
Recherches "plusieurs pathologies"
EXPRESS
Low level of genomic alteration to predict exceptional and unexpected response to targeted thÚrapies in patients with solid tumors.;EXPRESS : EXcePtional RESponSe
Paris
CHRISTOPHE LE TOURNEAU
Gynécologie
GM102
OPEN, NON CONTROLLED, MULTICENTER, FIRST-IN-HUMAN STUDY FOR THE EVALUATION OF THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF GM102 IN PATIENTS WITH ADVANCED PRETREATED GYNECOLOGICAL CANCER
Paris
CHRISTOPHE LE TOURNEAU